Chimeric Antigen Receptor T Cell (CAR T) Therapy: A Revolutionary Cancer Treatment on the Horizon

What is CAR T Cell Therapy?

T cell therapy, also called adoptive cell transfer (ACT) therapy, is a type of immunotherapy that uses a patient’s own T cells to fight cancer. In CAR T cell therapy, a patient’s T cells are altered to better recognize and attack cancer cells. Specifically, T cells are collected from a patient and engineered to express a chimeric antigen receptor (CAR) that targets a specific protein on the cancer cell surface. Once infused back into the patient, these CAR T cells can multiply and trigger an immune response against cancer cells carrying that target.

History and Development of CAR T Cell Therapy

The concept of CAR T Cell Therapy was proposed in the late 1980s, but its modern development started in the early 2000s. Dr. Carl June and colleagues at the University of Pennsylvania developed the first successful CAR T cell therapy by targeting CD19 on B cell cancers. In August 2017, Novartis’ Kymriah became the first CAR T cell therapy approved by the FDA for the treatment of B cell acute lymphoblastic leukemia in children and young adults. In May 2018, Gilead’s Yescarta was approved for treatment of large B cell lymphoma. Since then, research has expanded to targeting other cancers.

Mechanism of Action
T cells are collected from a patient through a process called leukapheresis. The gene for the CAR receptor is then inserted into the T cells, usually using a viral or non-viral vector. The CAR incorporates an antibody-derived targeting domain to recognize a specific antigen on cancer cells. It also contains T cell activating domains that trigger immune responses once binding occurs. The engineered CAR T cells are then expanded in large numbers and infused back into the patient. Once in the body, the CAR T cells can propagate, persist, and eliminate cancer cells that express the target antigen.

Clinical Trials and Results So Far
Clinical trials have demonstrated extremely high response rates in blood cancers such as acute lymphoblastic leukemia and lymphoma which express the CAR T cell target CD19. In some trials, over 80% of treated patients experienced complete remission. However, results have been more modest against solid tumors. Challenges include the heterogeneous nature of solid tumors, immunosuppressive tumor microenvironments, and availability of suitable targets. Ongoing research focuses on improving CAR T cell design, combination therapies, and targeting new antigens. Late-stage clinical trials are also evaluating CAR T cell therapies for other blood cancers and solid tumors like multiple myeloma and mesothelioma.

Commercialization Status and Outlook
Novartis and Gilead have successfully commercialized the first two CAR T cell therapies in relapsed/refractory blood cancers. Additional therapies are in late-stage development by companies like Bristol Myers Squibb, Bluebird Bio, and Juno Therapeutics. The overall CAR T cell therapy market is expected to grow exponentially and reach over $10 billion by 2025 according to some estimates. However, development challenges remain in expanding the approach to solid tumors. The complex logistics of engineering and manufacturing individualized cell therapies also present hurdles. If these hurdles can be overcome through innovation, CAR T cell therapy holds immense promise as a revolutionary new class of cancer treatment.

Manufacturing and Logistical Challenges
One of the major difficulties with CAR T cell therapy is that it requires engineering and expanding patient’s own immune cells ex vivo before reinfusion. This complex manufacturing process can take several weeks and is not standardized across different CAR constructs. It also involves significant costs that pose reimbursement issues. Another challenge lies in the short-term nature of the cell products – engineered CAR T cells may not persist long-term in patients. Emerging approaches to address these challenges include developing ‘universal’ or allogeneic CAR T cell products from healthy donors as well as gene editing to generate CAR T cells with longer lives. Overall, innovation in manufacturing platforms and distribution networks will be key toscaling up this personalized therapy.

Toxicity Management
While CAR T cell therapy can drive high cancer response rates, it also carries significant risks of severe cytokine release syndrome and neurotoxicity due to healthy organ damage. These toxicities are caused by overly exuberant T cell activation and require intensive care. Risk mitigation strategies include developing next-gen CARs with tunable activity, combination with other therapies, and engineering checkpoint inhibitor resistant T cells. Biomarkers to predict toxicity are also actively sought. Managing therapy-related toxicities will remain crucial as CAR T cells are tested against broader tumor types.

Future Outlook and Conclusion
The field of CAR T cell therapy has advanced rapidly since the approval of the first two products just a few years ago. Ongoing innovations to optimize T cell engineering, overcome manufacturing limitations, improve targeting of solid tumors, and better manage toxicities hold promise to further unleash the potential of this revolutionary approach. If barriers are overcome, CAR T cells may transform cancer treatment by delivering long-term remissions for patients with even advanced malignancies. While challenges remain, CAR T cell therapy is undoubtedly reshaping the cancer immunotherapy landscape for the better and ushering in a new era of personalized medicine.

 

Get more insights on CAR T Cell Therapy